Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.

被引：0
|
作者：
Kaseb, Ahmed Omar [1 ]
Pestana, Roberto Carmagnani [1 ]
Vence, Luis M. [1 ]
Blando, Jorge M. [1 ]
Singh, Shalini [1 ]
Ikoma, Naruhiko [1 ]
Vauthey, Jean-Nicolas [1 ]
Allison, James Patrick [1 ]
Sharma, Padmanee [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 08期
关键词：
D O I：
10.1200/JCO.2019.37.8_suppl.52
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
52
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).
    Ciccarese, Chiara
    Verzoni, Elena
    Bimbatti, Davide
    Buti, Sebastiano
    Calabro, Fabio
    Galli, Luca
    Scagliarini, Sarah
    Fornarini, Giuseppe
    Baldessari, Cinzia
    Bilancia, Domenico
    Facchini, Gaetano
    Cattrini, Carlo
    Masini, Cristina
    Giganti, Maria Olga
    Scandurra, Giuseppa
    Nole, Franco
    Berruti, Alfredo
    Milella, Michele
    Antonuzzo, Lorenzo
    Iacovelli, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS494 - TPS494
  • [42] A phase 3, open-label, randomized study of nivolumab plus ipilimumab or standard of care (SoC) vs SoC alone in patients (pts) with previously untreated unresectable or metastatic urothelial carcinoma (mUC; CheckMate 901).
    Galsky, Matt D.
    Powles, Thomas
    Li, Shengting
    Hennicken, Delphine
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
    Lucas, Minke W.
    Scolyer, Richard A.
    van de Wiel, Bart A.
    Menzies, Alexander M.
    Lopez-Yurda, Marta I.
    van Akkooi, Alexander Christopher Jonathan
    van Houdt, Winan J.
    Saw, Robyn P. M.
    Torres Acosta, Alex
    Lo, Serigne N.
    Hospers, Geke
    Carlino, Matteo S.
    de Groot, Jan Willem
    Kapiteijn, Ellen
    Suijkerbuijk, Karijn
    Rutkowski, Piotr
    Sandhu, Shahneen
    van der Veldt, Astrid Aplonia Maria
    Long, Georgina V.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL)
  • [44] Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial
    Ascierto, Paolo A. A.
    Mandala, Mario
    Ferrucci, Pier Francesso
    Guidoboni, Massimo
    Rutkowski, Piotr
    Ferraresi, Virginia
    Arance, Ana
    Guida, Michele
    Maiello, Evaristo
    Gogas, Helen
    Richtig, Erika
    Fierro, Maria Teresa
    Lebbe, Celeste
    Helgadottir, Hildur
    Queirolo, Paola
    Spagnolo, Francesco
    Tucci, Marco
    Del Vecchio, Michele
    Gonzales Cao, Maria
    Minisini, Alessandro Marco
    De Placido, Sabino
    Sanmamed, Miguel F. F.
    Mallardo, Domenico
    Curvietto, Marcello
    Melero, Ignacio
    Palmieri, Giuseppe
    Grimaldi, Antonio M.
    Giannarelli, Diana
    Dummer, Reinhard
    Sileni, Vanna Chiarion
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (02) : 212 - +
  • [45] CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
    Hammers, Hans J.
    Plimack, Elizabeth R.
    Sternberg, Cora
    McDermott, David F.
    Larkin, James M. G.
    Ravaud, Alain
    Rini, Brian I.
    Sharma, Padmanee
    Bhagavatheeswaran, Prabhu
    Gagnier, Paul
    Motzer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial (vol 17, pg 888, 2016)
    Antonia, S. J.
    Lopez-Martin, J. A.
    Bendell, J.
    LANCET ONCOLOGY, 2016, 17 (07): : E270 - E270
  • [47] Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial (vol 17, pg 883, 2016)
    Antonia, S. J.
    Lopez-Martin, J. A.
    Bendell, J.
    LANCET ONCOLOGY, 2019, 20 (02): : E70 - E70
  • [48] Efficacy and safety of nivolumab plus ipilimumab versus nivolumab alone in patients with advanced melanoma: a systematic review and meta-analysis
    Cui, Shuting
    Sun, Xiaozhe
    Gao, Junxi
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (05) : 283 - 291
  • [49] Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.
    Laengle, Johannes
    Kuehrer, Irene
    Pils, Dietmar
    Kabiljo, Julijan
    Stift, Judith
    Herbst, Friedrich
    Dauser, Bernhard
    Monschein, Matthias
    Razek, Peter
    Haegele, Stefanie
    Huller, Wolfgang
    Fuegger, Reinhold
    Geinitz, Hans
    Petzer, Andreas L.
    Bitterman, Clemens
    Laengle, Friedrich
    Tamandl, Dietmar
    Widder, Joachim
    Schmid, Rainer
    Bergmann, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] A phase II study of nivolumab, ipilimumab plus bicalutamide in metastatic breast cancer
    Page, D. B.
    Kaur, L.
    Hong, E. C. C.
    Su, A.
    Moxon, N.
    Mellinger, S.
    Kelly, T.
    Kelley, A.
    Fredrich, N.
    Seino, A.
    Liberatore, G.
    Conlin, A. K.
    Topp, Z.
    Perlewitz, K.
    Stanton, S.
    Wu, Y.
    Traina, T. A.
    Gucalp, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S379 - S380
12345